[Skip to Navigation]
Comment & Response
March 2, 2022

Do Not Rule Out Double-blind Placebo Run-in Periods for Randomized Clinical Trials

Author Affiliations
  • 1Signant Health, Boston, Massachusetts
JAMA Psychiatry. 2022;79(4):381. doi:10.1001/jamapsychiatry.2022.0048

To the Editor In their systematic review and meta-analysis, Scott and colleagues1 concluded that the practice of placebo run-in (PRI) periods in randomized clinical trials (RCTs) of antidepressants should be discontinued. They examined 174 studies of major depressive disorder that used single-blind PRI designs and found less robust within-group changes in both the experimental drug and placebo groups and equivalence in the drug-placebo outcome differences compared with studies that did not use PRI designs.

Add or change institution